Anteris Technologies Global Corp. — Board/Management Information 2025

Mar 5, 2025

==> picture [118 x 33] intentionally omitted <==

Appointment of Company President and Non-Independent Director

Minneapolis, USA and Brisbane, Australia 6 March 2025: Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) ( Anteris or the Company ) advises that on 6 March 2025 the Board of Directors (the “ Board ”) appointed David St Denis as the Company’s President and as a Class II director of the Board, effective immediately. As a non-independent director, Mr. St Denis will not serve on any committees of the Board.

Mr. St Denis, 56, has served as Chief Operating Officer of the Company since July 2017 and the Chief Executive Officer of v2vmedtech, inc. since April 2023. Mr. St Denis also served as Chief Financial Officer of v2vmedtech from April 2023 to September 2023. Prior to his appointment as Chief Operating Officer of the Company, Mr. St Denis served as Head of Commercial Operations for Europe and Canada at Merck since 2013, and prior to that served as Head of Operations for Emerging Markets at Merck since 2008. In addition, Mr. St Denis had held multiple leadership roles at Millennium Pharmaceuticals, Inc, now Takeda Pharmaceutical Company, from 1996 to 2006, and provided strategic consulting services to such company from 2006 to 2008. Mr. St Denis has a Bachelor of Science from the University of Connecticut, a Master of Arts from Boston University and an MBA in Global Management and International Marketing from Babson College — Franklin W. Olin Graduate School of Business.

As of the date of this Current Report on Form 8-K, there has been no material amendment to Mr. St Denis’s current compensatory arrangements, nor has he received any grants or awards in connection with his appointment as President or as director of the Board. In accordance with ASX Listing Rule 3.16.4, a summary of the material terms of the employment of Mr. St Denis is set out in the Annexure to this announcement.

There are no arrangements or understandings between Mr. St Denis and any other persons pursuant to which Mr. St Denis was named as President of the Company or a director of the Board. There are no family relationships between Mr. St Denis and any director or executive officer of the Company. Mr. St Denis has no direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

In connection with his previous appointment as Chief Operating Officer, the Company entered into its standard form of indemnification agreement for directors and officers with Mr. St Denis, which requires the Company to indemnify him against certain liabilities that may arise as a result of his status or service as a director or officer.

ENDS

About Anteris[®]

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a sciencedriven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

860 Blue Gentian Road, Suite 340 Eagan, MN, 55121 United States T: +1 651 493 0606 info.us@anteristech.com

==> picture [28 x 30] intentionally omitted <==

Anteris Technologies Global Corp. BRISBANE | MINNEAPOLIS | GENEVA | MALAGA

Toowong Tower, Level 3, Suite 302 9 Sherwood Road, Toowong QLD 4066, Australia T: +61 1300 550 310 info.au@anteristech.com ARBN: 677 960 235

anteristech.com

==> picture [93 x 26] intentionally omitted <==

Anteris’ lead product, the DurAVR[®] Transcatheter Heart Valve ( THV ), was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially lifethreatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR[®] THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR[® ] THV is made using a single piece of molded ADAPT[®] tissue, Anteris’ patented anti-calcification tissue technology. ADAPT[®] tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR[®] THV System is comprised of the DurAVR[®] valve, the ADAPT[®] tissue, and the balloon-expandable ComASUR[®] Delivery System.

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Board of Directors.

For more information:

Investor Relations investors@anteristech.com Debbie Ormsby Anteris Technologies Global Corp. +61 1300 550 310 | +61 7 3152 3200

Investor Relations (US) Malini Chatterjee, Ph.D. mchatterjee@bplifescience.com Blueprint Life Science Group +1 917 330 4269

Website www.anteristech.com X @AnterisTech Facebook www.facebook.com/anteristech LinkedIn https://www.linkedin.com/company/anteristech

==> picture [28 x 30] intentionally omitted <==

2

==> picture [93 x 26] intentionally omitted <==

Annexure – Material Terms of Employment – Mr David St Denis

Annexure – Material Terms of	Employment – Mr David St Denis
Position	Chief Operating Officer, President and Director (Class II)
Commencement Date	Commenced as Chief Operating Officer in July 2017 Commenced as President and Director (Class II) on 6 March 2025
Total Fixed Remuneration	USD$475,000
Short Term Incentive	Subject to the achievement of certain key performance targets (as determined by the Board), Mr. St Denis is entitled to receive an annual incentive bonus of up to 80% of his Total Fixed Remuneration. Mr. St Denis is also entitled to participate in the Company’s Share Price Performance Plan, under which, at the discretion of the Board, Mr. St Denis may receive cash payments determined by reference to the performance of the Company’s shareprice over time.
Long Term Incentives	Eligible to participate in the Company’s equity incentive plan, under which it is anticipated that, in addition to equity incentives previously issued to Mr. St Denis, Mr. St Denis will be issued, on an annual basis starting with the 2026 calendar year, long-term incentive compensation awards with a total aggregate target grant value of USD$2,000,000, which vest upon the achievement of certain vesting conditions as determined bythe Board.
Termination Rights	The Company may terminate Mr. St Denis’ employment without “cause”, and Mr. St Denis may terminate his employment with the Company on 3 months’ written notice. If the Company terminates Mr. St Denis’ employment without “cause”, subject to Mr. St Denis releasing the Company and its affiliates from all claims, the Company is required to continue to pay Mr. St Denis his Total Fixed Remuneration for a period of nine months, and also reimburse Mr. St Denis for Continuation of Health Coverage (COBRA) premium payments until Mr. St Denis becomes eligible for coverage under anotherplan(for a maximumperiod of nine months).
Restraints	The employment agreements includes customary non-competition, non- solicitation, intellectualproperty, and confidentiality provisions.

==> picture [28 x 30] intentionally omitted <==

3